- Global Pharma News & Resources

Diabetic Peripheral Neuropathy - Pipeline Insight 2018 -

The "Diabetic Peripheral Neuropathy - Pipeline Insight, 2018" drug pipelines has been added to's offering.

'Diabetic Peripheral Neuropathy - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Diabetic Peripheral Neuropathy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Diabetic Peripheral Neuropathy pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Diabetic Peripheral Neuropathy Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

Companies Mentioned

  • Achelios Therapeutics Inc
  • Celgene Corp
  • Commence Bio Inc
  • KPI Therapeutics Inc
  • Medifron DBT Co Ltd
  • Relief Therapeutics Holding AG
  • ViroMed Co Ltd

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 21-Dec-2018